glp 1 pediatric Two MASLD Publications: Call for Action and Use of GLP-1 RAs GLP-1 medications for weight loss

Last year, FDAacting through the Office of Prescription Drug Promotion (OPDP) within the Center for Drug Evaluation and Research (CDER)issued a high volume of untitled and warning letters as part of a broader push against directtoconsumer (DTC) drug advertising, including 58 letters addressing claims about compounded GLP1s (e.g., semaglutide and tirzepatide) and other compounded products (e.g., sildenafil and tadalafil).[2] By mid2026, activity appeared to taper offraising the question whether FDA had shifted priorities, for example due to personnel changes, or simply paused the effort

After 1 min, stop solution was added to terminate the reaction

Lynch GS

and for patients receiving placebo, -0.2%

Critical Considerations & Current Status Investigational Drug: Cagrilintide is NOT approved for any use